Abstract Purpose Symptomatic adverse events (AEs) are monitored by clinicians as part of
all US-based clinical trials in cancer via the US National Cancer Institute's Common …

Systematic capture of the patient perspective can inform the development of new cancer
therapies. Patient-reported outcomes (PROs) are commonly included in cancer clinical trials; …

Cancer clinical trials have relied on overall survival and measures of tumor growth or
reduction to assess the efficacy of a drug. However, benefits are often accompanied by …

As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …

Symptomatic toxicities associated with anticancer treatments, such as nausea and vomiting,
are frequently underreported by clinicians, even when data are prospectively collected …

Importance Agreement between patient-and practitioner-reported toxic effects during
chemoradiotherapy for head and neck cancer is unknown. Objective To compare patient …

Background PRO-CTCAE is a library of items that measure cancer treatment-related
symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN …

Purpose There is increasing interest to use patient-reported outcome (PRO) measures to
evaluate symptomatic adverse events (AEs) in cancer treatment trials. However, there are …

Appropriate safety evaluations of anticancer drugs are crucial to assess their benefit–risk
ratio. Substantial evidence shows that clinicians under-report harm in clinical trials, and at …

Importance Patient perspective on chemotherapy-related adverse effects is being
increasingly acknowledged both in experimental clinical trials and in clinical practice …